An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.
- 30 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Jul 2017.
- 31 Jan 2017 Planned initiation date changed from 1 Jan 2017 to 1 Feb 2017.